Abstract
Background Throughout the UK’s Covid-19 vaccination campaign, responsibility for vaccinating housebound patients has rested with individual GP surgeries, posing them a difficult logistical challenge (the travelling salesman problem). In response to demand from GPs, and a lack of existing solutions tailored specifically to vaccination, VaxiMap was created. This tool provides optimal routes for vaccine delivery and has been free to all users since its inception in January 2021.
Methods VaxiMap generates optimal routes subject to the constraint that the number of patients per route should be fixed. This ensures that a known quantity of vaccine can be set aside for each route and minimises wastage. The user need only upload an Excel spreadsheet of patient postcodes to be visited. A divide-and-conquer approach of iterative k-means clustering followed by within-cluster route optimisation is used to generate the routes.
Findings We find substantial savings in the time taken to plan vaccinations, as well as savings in the time taken to visit housebound patients. We estimate total savings to date of 4,700 hours of practitioner time, equivalent to 2.5 work-years, or approximately £91k at typical practitioner salaries.
Interpretation The adoption of VaxiMap yielded both time and cost savings for GP surgeries and accelerated the UK’s Covid-19 vaccination campaign at a critical moment.
Funding Financial support for VaxiMap was provided by Magdalen College, Oxford, Oxford University Innovation, and JHubMed, part of UK Strategic Command. These parties were not involved in the preparation of this manuscript.
Competing Interest Statement
TK, RS and Oxford University Innovation are shareholders in Vaxine Limited, a registered company in England and Wales (number 13182914), which owns the intellectual property of Vaximap. The authors declare no other conflicts of interest.
Funding Statement
Financial support was provided by Magdalen College, Oxford, Oxford University Innovation, and JHubMed, part of UK Strategic Command. These parties were not involved in the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work has been classified as service development and evaluation by the Medical Sciences Interdivisional Research Ethics Committee at the University of Oxford, and does not therefore require ethical review (CUREC application R79436/RE001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
